Adrenoreceptors, platelet reactivity and clopidogrel resistance.
Xiang
Yao-Zu
YZ
D001241:Aspirin; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D009638:Norepinephrine / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D018341:Receptors, Adrenergic, alpha-2 / Q000097:blood / Q000187:drug effects*; D018048:Receptors, Purinergic P2 / Q000097:blood / Q000187:drug effects; D058925:Receptors, Purinergic P2Y12; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure
C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D018341:Receptors, Adrenergic, alpha-2; D018048:Receptors, Purinergic P2; D058925:Receptors, Purinergic P2Y12; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin; D009638:Norepinephrine